title: [The experience in non-relative allogenic transplantation of stem hemopoietic cells in the Clinic of Bone Marrow Transplantation at I.P. Pavlov St-Petersburg Medical Academy].
abstract: OBJECTIVE
  To evaluate efficacy of allogenic transplantation of hemopoietic stem cells (allo-THSC) from non-relative donor in patients with hematological diseases in the Clinic of Bone Marrow Transplantation at L.P. Pavlov St-Petersburg Medical Academy for the period 2000-2006.
  
  
  METHODS
  A total of 84 allo-THSC from non-relative donor to patients aged from 10 months to 65 years (median 18 months, 44 years) was carried out.
  
  
  RESULTS
  Six-year overall survival (OS) in all the patients was 51.4%, in remission of AML--66.7%, ALL--33%, depending on the presence or absence of acute reaction graft versus host reaction (GVHR)--54 and 50.9%, chronic FVHR--75.6 and 58.2%, blood group compatibility or incompatibility in donor/recipient pairs--58.4 and 47.9%, by gender--61.4 and 40.6%, in use of HSC of the bone marrow--58.3%, peripheral blood--26.7%. OS in the dose of transplanted CD 34+ cells per 1 kg body mass < 5.0 x 10(6)/kg--173%, in the dose 5.0--8.0 x 10(6)/kg--38.8%, > 8.0 x 10(6)/kg--35.5%. Acute GVHR developed in 56% patients, chronic--in 20%, hemorrhagic cystitis--in 27.7%, bacterial, cytomegalovirus and fungal infection--in 10, 70 and 30%, respectively. The causes of death were acute GVHR (20%), infection 99%), polyorganic failure (4%), transplant rejection (5.3%), recurrence (18.7%).
  
  
  CONCLUSIONS
  Bone marrow transplantation clinics in the Russian Federation must develop all kinds of allo-THSC--relative, non-relative and haploidentical using bone marrow, peripheral blood, umbilical blood as the source of HSC. It is necessary to create a national register of non-relative donors.
authors.forename: B V
authors.initials: BV
authors.lastname: Afanas'iev
authors.forename: L S
authors.initials: LS
authors.lastname: Zubarovskaia
authors.forename: E V
authors.initials: EV
authors.lastname: Semenov
authors.forename: N E
authors.initials: NE
authors.lastname: Ivanova
authors.forename: A L
authors.initials: AL
authors.lastname: Alianskiĭ
authors.forename: E V
authors.initials: EV
authors.lastname: Morozova
authors.forename: N B
authors.initials: NB
authors.lastname: Mikhaĭlova
authors.forename: E I
authors.initials: EI
authors.lastname: Darskaia
authors.forename: M A
authors.initials: MA
authors.lastname: Estrina
authors.forename: A A
authors.initials: AA
authors.lastname: Golovacheva
authors.forename: E V
authors.initials: EV
authors.lastname: Babenko
authors.forename: S N
authors.initials: SN
authors.lastname: Bondarenko
authors.forename: A A
authors.initials: AA
authors.lastname: Ganapiev
authors.forename: M P
authors.initials: MP
authors.lastname: Bogomol'nyĭ
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D002648:Child; D002675:Child, Preschool; D005260:Female; D006087:Graft vs Host Reaction; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D007223:Infant; D007938:Leukemia / Q000401:mortality* / Q000601:surgery*; D008297:Male; D008875:Middle Aged; D016019:Survival Analysis; D014019:Tissue Donors; D014184:Transplantation, Homologous; D016896:Treatment Outcome